CRISPR Therapeutics (CRSP) Projected to Post Earnings on Wednesday

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) will likely be posting its quarterly earnings results before the market opens on Wednesday, February 19th. Analysts expect CRISPR Therapeutics to post earnings of ($1.15) per share and revenue of $8.06 million for the quarter.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, analysts expect CRISPR Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

CRISPR Therapeutics Trading Down 4.8 %

CRSP traded down $2.56 during trading hours on Thursday, hitting $50.46. 2,969,457 shares of the company's stock were exchanged, compared to its average volume of 2,428,653. The firm has a market cap of $4.33 billion, a P/E ratio of -11.55 and a beta of 1.67. CRISPR Therapeutics has a 12-month low of $36.52 and a 12-month high of $91.10. The firm has a 50 day moving average of $42.06 and a 200 day moving average of $46.04.

Insider Activity

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the firm's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the transaction, the chief executive officer now directly owns 181,540 shares in the company, valued at approximately $10,002,854. This trade represents a 7.63 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.10% of the company's stock.

Analyst Ratings Changes

Several research analysts have commented on CRSP shares. Chardan Capital lowered their price target on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating for the company in a report on Thursday, February 13th. Evercore ISI upgraded shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and boosted their price target for the stock from $60.00 to $99.00 in a report on Friday, February 14th. Truist Financial boosted their price target on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. JMP Securities reiterated a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $74.40.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.